FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2126185716> ?p ?o ?g. }

• W2126185716 abstract "Abstract Background Trastuzumab is currently approved for the clinical treatment of breast and gastric cancer patients with HER-2 positive tumors, but not yet for the treatment of esophageal carcinoma patients, whose tumors typically show 5 ~ 35% HER-2 gene amplification and 0 ~ 56% HER-2 protein expression. This study aimed to investigate the therapeutic efficacy of Trastuzumab in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models. Methods PDECX models were established by implanting patient esophageal squamous cell carcinoma (ESCC) tissues into immunodeficient (SCID/nude) mice. HER-2 gene copy number (GCN) and protein expression were determined in xenograft tissues and corresponding patient EC samples by FISH and IHC analysis. Trastuzumab anti-tumor efficacy was evaluated within these PDECX models (n = 8 animals/group). Furthermore, hotspot mutations of EGFR, K-ras, B-raf and PIK3CA genes were screened for in the PDECX models and their corresponding patient’s ESCC tissues. Similarity between the PDECX models and their corresponding patient’s ESCC tissue was confirmed by histology, morphology, HER-2 GCN and mutation. Results None of the PDECX models (or their corresponding patient’s ESCC tissues) harbored HER-2 gene amplification. IHC staining showed HER-2 positivity (IHC 2+) in 2 PDECX models and negativity in 3 PDECX models. Significant tumor regression was observed in the Trastuzumab-treated EC044 HER-2 positive model (IHC 2+). A second HER-2 positive (IHC 2+) model, EC039, harbored a known PIK3CA mutation and showed strong activation of the AKT signaling pathway and was insensitive to Trastuzumab treatment, but could be resensitised using a combination of Trastuzumab and AKT inhibitor AZD5363. In summary, we established 5 PDECX mouse models and demonstrated tumor regression in response to Trastuzumab treatment in a HER-2 IHC 2+ model, but resistance in a HER-2 IHC 2+/PIK3CA mutated model. Conclusions This study demonstrates Trastuzumab-induced tumor regressions in HER-2 positive tumors, and highlights PIK3CA mutation as a potential resistance mechanism to Trastuzumab treatment in pre-clinical patient-derived EC xenograft models." @default.
• W2126185716 created "2016-06-24" @default.
• W2126185716 creator A5004197553 @default.
• W2126185716 creator A5006823146 @default.
• W2126185716 creator A5008907152 @default.
• W2126185716 creator A5010917374 @default.
• W2126185716 creator A5014156884 @default.
• W2126185716 creator A5023992256 @default.
• W2126185716 creator A5029327882 @default.
• W2126185716 creator A5035260546 @default.
• W2126185716 creator A5038467374 @default.
• W2126185716 creator A5045878729 @default.
• W2126185716 creator A5048874956 @default.
• W2126185716 creator A5054898123 @default.
• W2126185716 creator A5054958071 @default.
• W2126185716 creator A5056158655 @default.
• W2126185716 creator A5056975844 @default.
• W2126185716 creator A5057683878 @default.
• W2126185716 creator A5062680852 @default.
• W2126185716 creator A5080236734 @default.
• W2126185716 creator A5081178435 @default.
• W2126185716 creator A5082669026 @default.
• W2126185716 date "2012-08-30" @default.
• W2126185716 modified "2023-09-23" @default.
• W2126185716 title "Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models" @default.
• W2126185716 cites W1953502397 @default.
• W2126185716 cites W1964230131 @default.
• W2126185716 cites W1973910769 @default.
• W2126185716 cites W1978013017 @default.
• W2126185716 cites W1982507863 @default.
• W2126185716 cites W1987009448 @default.
• W2126185716 cites W1995041998 @default.
• W2126185716 cites W1998534698 @default.
• W2126185716 cites W1999070116 @default.
• W2126185716 cites W2005399294 @default.
• W2126185716 cites W2006038382 @default.
• W2126185716 cites W2016211783 @default.
• W2126185716 cites W2017984483 @default.
• W2126185716 cites W2020372547 @default.
• W2126185716 cites W2021208496 @default.
• W2126185716 cites W2032129723 @default.
• W2126185716 cites W2039295972 @default.
• W2126185716 cites W2045324973 @default.
• W2126185716 cites W2069249497 @default.
• W2126185716 cites W2073165102 @default.
• W2126185716 cites W2092862243 @default.
• W2126185716 cites W2100439220 @default.
• W2126185716 cites W2103875073 @default.
• W2126185716 cites W2106844031 @default.
• W2126185716 cites W2106856635 @default.
• W2126185716 cites W2113720647 @default.
• W2126185716 cites W2114287880 @default.
• W2126185716 cites W2117497402 @default.
• W2126185716 cites W2120943945 @default.
• W2126185716 cites W2125229905 @default.
• W2126185716 cites W2129172946 @default.
• W2126185716 cites W2132094713 @default.
• W2126185716 cites W2132157071 @default.
• W2126185716 cites W2133105825 @default.
• W2126185716 cites W2136043430 @default.
• W2126185716 cites W2136745780 @default.
• W2126185716 cites W2141325836 @default.
• W2126185716 cites W2146944629 @default.
• W2126185716 cites W2152654745 @default.
• W2126185716 cites W2156182078 @default.
• W2126185716 cites W2158734599 @default.
• W2126185716 cites W2161422104 @default.
• W2126185716 cites W2169560977 @default.
• W2126185716 cites W2318605753 @default.
• W2126185716 cites W3148490103 @default.
• W2126185716 cites W4231231079 @default.
• W2126185716 cites W4252560545 @default.
• W2126185716 doi "https://doi.org/10.1186/1479-5876-10-180" @default.
• W2126185716 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3485623" @default.
• W2126185716 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22935382" @default.
• W2126185716 hasPublicationYear "2012" @default.
• W2126185716 type Work @default.
• W2126185716 sameAs 2126185716 @default.
• W2126185716 citedByCount "40" @default.
• W2126185716 countsByYear W21261857162013 @default.
• W2126185716 countsByYear W21261857162014 @default.
• W2126185716 countsByYear W21261857162015 @default.
• W2126185716 countsByYear W21261857162016 @default.
• W2126185716 countsByYear W21261857162017 @default.
• W2126185716 countsByYear W21261857162018 @default.
• W2126185716 countsByYear W21261857162019 @default.
• W2126185716 countsByYear W21261857162020 @default.
• W2126185716 countsByYear W21261857162021 @default.
• W2126185716 countsByYear W21261857162022 @default.
• W2126185716 countsByYear W21261857162023 @default.
• W2126185716 crossrefType "journal-article" @default.
• W2126185716 hasAuthorship W2126185716A5004197553 @default.
• W2126185716 hasAuthorship W2126185716A5006823146 @default.
• W2126185716 hasAuthorship W2126185716A5008907152 @default.
• W2126185716 hasAuthorship W2126185716A5010917374 @default.
• W2126185716 hasAuthorship W2126185716A5014156884 @default.
• W2126185716 hasAuthorship W2126185716A5023992256 @default.
• W2126185716 hasAuthorship W2126185716A5029327882 @default.
• W2126185716 hasAuthorship W2126185716A5035260546 @default.
• W2126185716 hasAuthorship W2126185716A5038467374 @default.

• next